CONSORT diagram. Newly diagnosed unfavorable intermediate- and high-risk patients with prostate cancer were randomly assigned 2:1 to abiraterone, enzalutamide, leuprolide, and prednisone versus enzalutamide and leuprolide for 24 weeks followed by radical prostatectomy. (*) One patient allocated to the abiraterone, enzalutamide, leuprolide, and prednisone arm had a delay in radical prostatectomy by 2 months.